SCHEMBL267581

SCHEMBL267581

CC1(C)C(=O)[N]N(c2ccccc2)C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
ELANE P08246 3/20 0.43
ALDH1A1 P00352 6/20 0.41
GFER P55789 1/20 0.41
PGR P06401 1/20 0.41
GAA P10253 4/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 2/20 0.41
CHRM2 P08172 1/20 0.41
CYP3A4 P08684 1/20 0.41
CHRM1 P11229 1/20 0.41
TSHR P16473 1/20 0.41
PTGS1 P23219 1/20 0.41
DRD3 P35462 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LOX P28300 2/20 0.40
LOXL3 P58215 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420793 0.79 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1GFERPGRGAA
SCHEMBL9234143 0.74 SMN1; SMN2 (0.46) SMN1; SMN2ELANEALDH1A1GFERPGR
SCHEMBL16091682 0.69 SMN1; SMN2 (0.59) SMN1; SMN2ELANEALDH1A1GFERGAA
SCHEMBL10948887 0.69 ELANE (0.63) ELANEALDH1A1PGRGAAMARK3
SCHEMBL29332297 0.69 ELANE (0.50) SMN1; SMN2ELANEALDH1A1PGRMEN1
SCHEMBL18770503 0.68 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1GFERGAAMEN1
SCHEMBL3706828 0.67 SMN1; SMN2 (0.46) SMN1; SMN2ELANEALDH1A1GFERGAA
SCHEMBL17290523 0.67 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1GFERGAAMEN1
SCHEMBL11047547 0.67 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1GFERGAAMEN1
SCHEMBL6773284 0.66 SMN1; SMN2 (0.44) SMN1; SMN2ELANEALDH1A1GFERGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655070-B1 OXIDATION CATALYST ASAHI KASEI CHEMICALS CORP (JP) 2015-07-15 EP disclosed
US-8133834-B2 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-03-13 US disclosed
US-20100069670-A1 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2010-03-18 US disclosed
US-20060229471-A1 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2006-10-12 US disclosed
EP-1655070-A1 OXIDATION CATALYST Asahi Kasei Chemicals Corporation (JP) 2006-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069670-A1 Oxidation catalyst PPOX, SOD1, HAO2 SMN1; SMN2 4468/4885ELANE 1538/4885ALDH1A1 377/4885
US-20060229471-A1 Oxidation catalyst PPOX, SOD1, HAO2 SMN1; SMN2 4468/4885ELANE 1538/4885ALDH1A1 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.